Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2

Abstract

Background:We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB1 and CB2). In this study, we investigated the role of CB2 receptor in the anti-proliferative action of cannabinoids and the signal transduction triggered by receptor ligation.Methods:The human prostate cancer cell lines, namely PC-3, DU-145 and LNCaP, were used for this study. Cell proliferation was measured using MTT proliferation assay, [3H]-thymidine incorporation assay and cell-cycle study by flow cytometry. Ceramide quantification was performed using the DAG kinase method. The CB2 receptor was silenced with specific small interfering RNA, and was blocked pharmacologically with SR 144528. In vivo studies were conducted by the induction of prostate xenograft tumours in nude mice.Results:We found that the anandamide analogue, R(+)-Methanandamide (MET), as well as JWH-015, a synthetic CB2 agonist, exerted anti-proliferative effects in PC-3 cells. R(+)-Methanandamide- and JWH-015-induced cell death was rescued by treatment with the CB2 receptor antagonist, SR 144528. Downregulation of CB2 expression reversed the effects of JWH-015, confirming the involvement of CB2 in the pro-apoptotic effect of cannabinoids. Further analysing the mechanism of JWH-015-induced cell growth inhibition, we found that JWH-015 triggered a de novo synthesis of ceramide, which was involved in cannabinoid-induced cell death, insofar as blocking ceramide synthesis with Fumonisin B1 reduced cell death. Signalling pathways activated by JWH-015 included JNK (c-Jun N-terminal kinase) activation and Akt inhibition. In vivo treatment with JWH-015 caused a significant reduction in tumour growth in mice.Conclusions:This study defines the involvement of CB2-mediated signalling in the in vivo and in vitro growth inhibition of prostate cancer cells and suggests that CB2 agonists have potential therapeutic interest and deserve to be explored in the management of prostate cancer.

Cannabinoid Receptor 2 Suppresses Leukocyte Inflammatory Migration by Modulating the JNK/c-Jun/Alox5 Pathway

“…So it is possible that Cnr2 activation inhibits the phosphorylation of JNK and subsequently inhibits the transcription of alox5 through reducing the level of cAMP. Our finding that the JNKc-Jun-Alox5 axis could be efficiently blocked by Cnr2 signaling activation is consistent with the previous observation that Cnr2 activation inhibits human tumor cell proliferation by downregulating the phosphorylation of JNK (58).…”

Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy

“…Recently, numerous studies have evidenced the role of cannabinoids as potential anti-tumoral drugs owing to their ability to reduce tumor in different animal models, including glioma, 6 breast cancer 7,8 and prostate cancer. 9,10 Recent research has also reported that the synthetic cannabinoid WIN-55 212-2 inhibits HCC growth. 11,12 It has been described that D 9 -tetrahydrocannabinol (D 9 -THC), the main active constituent of marijuana, triggers human glioma cell death through stimulation of an ER stress pathway that activates autophagy and promotes apoptosis.…”

Cannabinoids as therapeutic agents in cancer: current status and future implications

“…The effects of anandamide in LNCaP, DU145, and PC3 cells were mediated through down-regulation of epidermal growth factor receptor (EGFR) and accumulation of ceramide [77]. JWH-015 triggered a de novo synthesis of ceramide, which induced cell death, followed by JNK (c-Jun N-terminal kinase) activation and Akt inhibition [76]. Effects of R(+)-Methanandamide and JWH-015 were rescued by treatment with SR 144528 in PC-3 cells [76, 79].…”